Skip to main content
N4 PHARMA PLC logo

N4 PHARMA PLC — Investor Relations & Filings

Ticker · N4P ISIN · GB00BYW8QM32 LEI · 213800I841D2RKMFK955 IL Professional, scientific and technical activities
Open in API
Filings indexed 840 across all filing types
Latest filing 2017-12-28 AGM Information
Country GB United Kingdom
Listing IL N4P

About N4 PHARMA PLC

https://n4pharma.com/

N4 Pharma PLC is a specialist pharmaceutical company focused on the development of Nuvec®, its proprietary silica nanoparticle delivery system. This platform technology is designed to enhance the cellular delivery and potency of nucleic acid-based treatments, such as vaccines and cancer therapies. The company's primary focus is on applying Nuvec® to enable advanced therapies for oncology and infectious diseases. N4 Pharma's business model involves developing and out-licensing its technology to pharmaceutical and biotechnology partners to improve the performance of new and existing drugs.

Recent filings

Filing Released Lang Actions
Result of General Meeting
AGM Information Classification · 1% confidence The document is identified by the RNS Number (4820A) and the header 'RNS Number'. The content explicitly announces the 'Result of General Meeting' and confirms that 'all resolutions were duly passed'. This directly relates to the outcome of a shareholder vote. According to the definitions, 'Declaration of Voting Results & Voting Rights Announcements' (DVA) covers official results from shareholder votes at any general meeting. Although it mentions a prior placing (CAP activity), the primary purpose of this specific announcement is reporting the meeting results.
2017-12-28 English
Exercise of Warrants and Total Voting Rights
Share Issue/Capital Change Classification · 1% confidence The document is identified by the 'RNS Number : 4364A' header, indicating it is a regulatory news service announcement from the London Stock Exchange. The content explicitly announces the 'Exercise of Warrants and Total Voting Rights' and the subsequent application for admission to trading of new ordinary shares. This action directly relates to a change in the company's capital structure (issuance of shares following warrant exercise) and an update to the total number of shares outstanding, which is relevant for shareholder notification thresholds (FCA's Disclosure and Transparency Rules). While it involves share issuance (SHA) and affects voting rights (DVA), the primary nature of this specific announcement—a formal notification of a capital event via RNS—fits best under the general regulatory filing category or a specific capital change. Since it details the issuance of shares following warrant exercise, 'Share Issue/Capital Change' (SHA) is highly relevant. However, given the context of an RNS announcement detailing a specific transaction impacting the share count, and the fact that warrant exercises leading to new share issuance are a form of capital change, SHA is a strong candidate. Alternatively, because it is a standard, short regulatory notification provided via RNS, 'RNS' (Regulatory Filings) is also plausible if SHA is reserved for broader capital structure announcements. Given the specific nature of the capital change (warrant exercise leading to new shares), SHA is more precise than the general RNS fallback. I will classify it as SHA because the core event is the issuance of new shares and the resulting change in total voting rights denominator.
2017-12-28 English
Grant of Options
Remuneration Information Classification · 1% confidence The document is an RNS announcement dated December 22, 2017, detailing the 'Grant of Options' to certain employees, including Persons Discharging Managerial Responsibilities (PDMRs). It explicitly lists the PDMRs (CEO, CFO, Head of Clinical Operations) and the number of options granted over ordinary shares. This type of filing, which reports personal share transactions or option grants by directors/executives, falls under the category of Director's Dealing (DIRS) according to standard regulatory reporting practices, even though the primary announcement mechanism is RNS. However, looking strictly at the provided definitions, the core content is the notification of transactions by insiders (PDMRs). While DIRS is for 'Director's Dealing', the content here is specifically about the *grant* of options to executives, which is a form of insider transaction reporting. Since the document is a formal regulatory announcement (RNS Number: 2118A) detailing transactions by management, it strongly aligns with Director's Dealing (DIRS). If DIRS were not available, RNS would be the fallback, but DIRS is more specific for insider transactions/grants.
2017-12-22 English
Filing of Patent
Regulatory Filings Classification · 1% confidence The document is identified by the 'RNS Number : 1479A' header and the concluding statement 'This information is provided by RNS The company news service from the London Stock Exchange'. The content announces a specific corporate action: the 'Filing of Patent' (Patent Cooperation Treaty application). This is a specific regulatory announcement that does not fit the definitions for 10-K, ER, IR, or IP. Since it is a formal regulatory announcement distributed via the RNS system and concerns intellectual property/legal matters, it is best classified as a general Regulatory Filing (RNS). Although it relates to intellectual property, 'IP' is defined as Investor Presentation, and 'LTR' is for Legal Proceedings Report (lawsuits/regulatory actions), not patent filings themselves. Therefore, RNS is the most appropriate general regulatory category for this specific announcement.
2017-12-22 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document explicitly contains the header 'RNS Number : 3872Z' and the footer 'This information is provided by RNS The company news service from the London Stock Exchange'. The content details a 'TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES' concerning a change in voting rights threshold (16%) due to an increase in issued share capital from warrant exercise. This type of mandatory disclosure regarding significant changes in share ownership or voting rights, especially when disseminated via the RNS system, falls under the category of general regulatory announcements. Since there is a specific category for 'Major Shareholding Notification' (MRQ), which deals with crossing ownership thresholds, and this document is a TR-1 form detailing exactly that, MRQ is the most precise fit. However, TR-1 forms are often categorized broadly under RNS if the specific nature (like director dealing or major holding) isn't explicitly listed, but MRQ is defined as 'Notification of changes in significant share ownership levels (crossing thresholds)'. Given the explicit crossing of the 16% threshold, MRQ is the best fit over the general RNS fallback.
2017-12-18 English
Exercise of Warrants and Total Voting Rights
Share Issue/Capital Change Classification · 1% confidence The document is identified by the 'RNS Number' header and contains an announcement regarding the 'Exercise of Warrants and Total Voting Rights'. This announcement details the issuance of new ordinary shares following warrant exercise and updates the total number of shares in issue, which directly impacts shareholder voting rights and disclosure thresholds under the FCA's Disclosure and Transparency Rules. This type of corporate action announcement, especially concerning share capital changes and voting rights implications, fits best under 'Share Issue/Capital Change' (SHA) or potentially 'Regulatory Filings' (RNS) if the primary focus was just the notification mechanism. However, since it explicitly details a capital change (issuance of new shares) and the resulting total voting rights, SHA is more specific. Given the context of the RNS number and the nature of the announcement (a specific corporate action update rather than a general regulatory filing fallback), SHA is the most appropriate classification.
2017-12-13 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.